Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA RAE BURGY

Allopathic & Osteopathic Physicians Dermatology

NPI
1275826521
CMS profile
1388571
Location
COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,433.55

89 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,433.55 89

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA RAE BURGY

NPI 1275826521 · CMS profile ID 1388571

Allopathic & Osteopathic Physicians / Dermatology

COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275826521?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA RAE BURGY, NPI 1275826521, CMS profile ID 1388571. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275826521?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JESSICA RAE BURGY, NPI 1275826521, CMS profile ID 1388571. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275826521?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JESSICA RAE BURGY, NPI 1275826521, CMS profile ID 1388571, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275826521?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

89 matching records · $1,433.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 89 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–89 of 89.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.6006/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832654687 CMS
LEO Pharma Inc. $15.1606/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842152493 CMS
Janssen Biotech, Inc. $19.1005/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788066383 CMS
AbbVie Inc. $20.7805/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190659 CMS
AbbVie Inc. $1.9905/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190657 CMS
AbbVie Inc. $6.4805/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190655 CMS
Galderma Laboratories, L.P. $17.8505/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855266165 CMS
AbbVie Inc. $3.5605/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190653 CMS
VYNE Pharmaceuticals Inc. $20.3405/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830829647 CMS
AbbVie Inc. $19.0705/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190651 CMS
AbbVie Inc. $13.5305/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190649 CMS
LEO Pharma Inc. $19.2204/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842152472 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.2504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849555655 CMS
PFIZER INC. $11.2904/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832712435 CMS
UCB, Inc. $29.5404/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807343521 CMS
Novartis Pharmaceuticals Corporation $20.0604/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812622353 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $17.7904/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851892059 CMS
AbbVie Inc. $4.5904/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190647 CMS
Janssen Biotech, Inc. $24.8504/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788066375 CMS
AbbVie Inc. $23.3603/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190645 CMS
VYNE Pharmaceuticals Inc. $38.0303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830817387 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.6503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849555653 CMS
AbbVie Inc. $5.3703/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190643 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $24.0503/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851892057 CMS
Janssen Biotech, Inc. $6.8702/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788066373 CMS
Janssen Biotech, Inc. $5.2902/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788066377 CMS
Galderma Laboratories, L.P. $19.2302/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855266163 CMS
Allergan, Inc. $12.3002/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792721347 CMS
AbbVie Inc. $14.8002/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190641 CMS
MAYNE PHARMA INC. $20.7302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849462017 CMS
Novartis Pharmaceuticals Corporation $23.9502/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812622355 CMS
AbbVie Inc. $21.8002/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190639 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $22.0001/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851892055 CMS
DERMIRA, INC. $24.4901/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 764403438 CMS
Amgen Inc. $22.0001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826360187 CMS
AbbVie Inc. $21.7801/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794190637 CMS
Janssen Biotech, Inc. $6.9801/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788066371 CMS
Lilly USA, LLC $26.3101/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819176123 CMS
Novartis Pharmaceuticals Corporation $24.1201/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812622351 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $883.64 57
PY2020 $1,143.63 62
PY2021 $1,433.55 89
PY2022 $1,535.61 93
PY2023 $2,775.38 172
PY2024 $3,132.39 175
PY2025 $3,517.75 226

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $291,085.40 26
PY2024 Recipient $1,717.54 9
PY2024 Principal investigator $209,734.74 18
PY2023 Recipient $18,892.00 1
PY2023 Principal investigator $4,205.52 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $4,270.00 12/15/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146525
Principal investigator 1 PFIZER INC. $1,109.55 12/03/2025 Non-covered Recipient Entity
Columbia Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228744992
Principal investigator 1 PFIZER INC. $1,109.55 11/26/2025 Non-covered Recipient Entity
Columbia Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228737497
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,500.00 11/20/2025 Non-covered Recipient Entity
Columbia Dermatology and Aesthetics
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431268
Principal investigator 1 SANOFI US SERVICES INC. $6,602.00 11/17/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146514
Principal investigator 1 PFIZER INC. $1,364.35 10/29/2025 Non-covered Recipient Entity
Columbia Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228741417
Principal investigator 1 SANOFI US SERVICES INC. $4,505.00 09/22/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146475
Principal investigator 1 PFIZER INC. $3,824.60 09/12/2025 Non-covered Recipient Entity
Columbia Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228759709
Principal investigator 1 SANOFI US SERVICES INC. $3,466.00 08/18/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146471
Principal investigator 1 SANOFI US SERVICES INC. $3,136.00 07/14/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146466
Principal investigator 1 Eli Lilly and Company $7,540.00 07/01/2025 Non-covered Recipient Entity
COLUMBIA DERMATOLOGY
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187878795
Principal investigator 1 SANOFI US SERVICES INC. $4,284.00 06/16/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146463
Principal investigator 1 SANOFI US SERVICES INC. $11,601.00 06/09/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146454
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 06/09/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146458
Principal investigator 1 PFIZER INC. $2,408.25 05/16/2025 Non-covered Recipient Entity
Jessica Burgy
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772805
Principal investigator 1 SANOFI US SERVICES INC. $4,615.00 04/28/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146450
Principal investigator 1 PFIZER INC. $2,485.20 04/09/2025 Non-covered Recipient Entity
Jessica Burgy
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781449
Principal investigator 1 Eli Lilly and Company $15,025.00 04/01/2025 Non-covered Recipient Entity
COLUMBIA DERMATOLOGY
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187876611
Principal investigator 1 Eli Lilly and Company $1,084.80 03/25/2025 Non-covered Recipient Entity
COLUMBIA DERMATOLOGY
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187878793
Principal investigator 1 SANOFI US SERVICES INC. $3,662.00 03/17/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146441
Principal investigator 1 PFIZER INC. $1,277.25 03/04/2025 Non-covered Recipient Entity
Jessica Burgy
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228787335
Principal investigator 1 SANOFI US SERVICES INC. $4,020.00 02/18/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146435
Principal investigator 1 PFIZER INC. $2,408.25 02/11/2025 Non-covered Recipient Entity
Jessica Burgy
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228751846
Principal investigator 1 SANOFI US SERVICES INC. $4,361.00 01/21/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146437
Principal investigator 1 SANOFI US SERVICES INC. $975.60 01/13/2025 Non-covered Recipient Entity
Columbia Dermatology
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226146430
Principal investigator 1 Eli Lilly and Company $175,151.00 01/08/2025 Non-covered Recipient Entity
COLUMBIA DERMATOLOGY
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187879649